Issue 20, 2018

Exploring the chelating capacity of 2-hydroxyphenyl-benzimidazole based hybrids with multi-target ability as anti-Alzheimer's agents

Abstract

Alzheimer's disease (AD) is the most common (60–70%) form of dementia in the elderly population. Its complex and multifactorial nature requires the development of drugs capable of hitting several disease targets, such as cholinergic dysfunction, oxidative stress, deposits of amyloid-β (Aβ) and metal ion dyshomeostasis. Two series of hybrids, mimetics of donepezil (DNP) and tacrine (TAC), containing a 2-hydroxyphenyl-benzimidazole (BIM) chelating moiety (DNP-BIM and TAC-BIM), were formerly developed and found to exhibit multi-target ability as anti-AD compounds. Due to the recognized role of metal ions as age triggers of AD, namely responsible for oxidative stress and Aβ aggregation, the copper and zinc chelating capacity is herein evaluated for two DNP-BIM hybrids (PP-BIM and PZ-BIM) and one TAC-BIM (TAC-BIM1) hybrid, as well as the role of copper in their Aβ aggregation inhibitory capacity. The compounds exhibit good chelating capacity towards Cu(II) (pCu ∼ 11) and moderate towards Zn(II) (pZn ∼ 6) in a 50% w/w DMSO/water medium, with the formation of 1 : 1 (MHL) and 1 : 2 (MH2L2, ML2 and MH−1L2) complex species involving the phenolic oxygen and the imidazole nitrogen N(3) of the BIM moiety in the coordination shell. All hybrids are able to improve the inhibition of self-induced Aβ aggregation, probably by ligand intercalation between the β-sheets of Aβ fibrils, with markedly higher inhibitory capacity for the tacrine conjugates than for the donepezil conjugates. Nevertheless, the compounds do no’t seem able to retrieve Cu(II) from Aβ peptide and so they may have no relevant role in Cu(II)-induced-Aβ aggregation.

Graphical abstract: Exploring the chelating capacity of 2-hydroxyphenyl-benzimidazole based hybrids with multi-target ability as anti-Alzheimer's agents

Article information

Article type
Paper
Submitted
08 jan. 2018
Accepted
05 sep. 2018
First published
21 sep. 2018

New J. Chem., 2018,42, 16503-16515

Exploring the chelating capacity of 2-hydroxyphenyl-benzimidazole based hybrids with multi-target ability as anti-Alzheimer's agents

S. Chaves, A. Hiremathad, D. Tomás, R. S. Keri, L. Piemontese and M. A. Santos, New J. Chem., 2018, 42, 16503 DOI: 10.1039/C8NJ00117K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements